The HE-4 protein is a promising specific marker for the diagnosis of malignant pelvic tumors. The paper presents the case of a 41-year-old patient with a multi-chamber ovarian tumor several centimeters in diameter suspected to be a primary ovarian cancer or a metastatic one of gastrointestinal origin. The value of the HE-4 marker which is highly specific for an ovarian cancer was within normal limits and amounted to 24.33 pmol/L. The patient underwent surgery involving the unilateral removal of adnexa and the greater omentum during which the sample from the second ovary was collected. Histologic examination revealed ovarian endometriosis; however, diagnosis of the gastrointestinal tract did not reveal any abnormalities. The case presented also confirms the excellent sensitivity of the HE-4 marker in very difficult clinical cases, as well as its utility in the differential diagnosis of advanced endometriosis and malignant ovarian diseases.
BuamahP.Benign conditions associated with rised serum CA 125 concentratiom. J Surg Oncol2000; 75: 264–5.
2.
HagaY., SakamotoK., EgamiH., YoshimuraR., AkagiM.Clinical significance of serum CA 125 values in patients with cancers of the digestive system. Am J Med Sci1986; 292: 30–4.
3.
RosenD., WangL., AtkinsonJ.Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol2005; 99: 267–77.
4.
Van ClasterB., TimmermanB., BourneT.Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus CA 125. J Natl Cancer Inst2007; 99: 1706–14.
5.
LangmarZ., NemethM., VleskoG., KiralyM., HornyakL., BoszeP.HE 4 – a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol2012; 32: 605–10.
6.
PartheenK., KristjansdottirB., SundfeldtK.Evaluation of ovarian cancer biomarkers HE 4 and CA 125 in women presenting with suspicious cystic mass. J Gynecol Oncol2012; 22: 244–52.
7.
MooreR.G., Jabre-RaughleyM., BrownA.K.Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol2010; 203: 1–6.
8.
MooreR.G., McMeekinD.S., BrownA.K.A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol2009; 112: 40–6.
9.
TingulstadS., HagenB., SkjeldestadF.E.Evaluation of risk of malignancy index based on serum CA 125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol1996; 103: 826–31.
10.
HolcombK., VuceticZ., MillerC., KnappR.C.Human epidydimis protein 4 offers superior specificity in the differentiation of benign and malignant adnxal masses in premenopausal women. Am J Obstet Gynecol2011; 205: 358 e 1-6.
11.
TrimbleE.L.The NIH consensus conference on ovarian cancer: screening, treatment and follw up. Gynecol Oncol1994; 55: S1–3.
12.
LoweK.A., ShahC., WallaceE.Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev2008; 17: 2480–7.
13.
BolstadN., OijordsbakkenM., NustadK., BjernerJ.Human epidydimis protein 4 references limits and natural variation in Nordic reference population. Tumour Biol2012; 33: 141–8.
14.
EscuederoJ.M., AugeJ.M., FilelaX., TorneA., PanisaJ., MolinaR.Comparison of Serum Human Epidydymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malihgnant and Nonmalignant Diseases. Clin Chem2011; 57: 1534–44.
15.
GalganoM., HamptonG., FriersonH.JrComprehensive analysis of HE 4 expression in normal and malignant human tissues. Mod Pathol2006; 19: 847–53.
16.
DrapkinR., HorstenH., LinY.Human epididymis protein 4 (HE 4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res2005; 65: 162–9.
17.
HellstromI., RaycraftJ., Hayden-LedbetterM.The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res2003; 63: 3695–700.
18.
KurataH., SasakiM., KaseH., YamamotoY., AokiY., TanakaK.Elevated serum CA 125 and 19-9 due to the spontaneus rupture of ovarian endometrioma. Eur J Obstet Gynecol Reprod Biol2002; 105: 75–6.
19.
ParkB.J., KimT.E., KimY.W.Massive peritoneal fluid and markedly elevated serum CA 125 and CA 19-9 levels associated with ovarian endometrioma. J Obstet Gynaecol Res2009; 35: 935–9.
20.
WangS., DongL., LiH., WangM.The application of HE 4 in diagnosis of gynaecological pelvic malignant tumor. Clinical Oncology and Cancer Research2009; 6: 72–4.
21.
ChangX., YeX., DongL.Human epididymis protein 4 (HE4) as Serum Tumor Biomarker in Patients with Ovarian Carcinoma. Int J Gynecol Cancer2011; 21: 852–8.
22.
ParkY., LeeJ.H., HongD.J., LeeE.Y., KimH.S.Diagnostic performance of HE 4 and CA 125 for detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem2011; 44: 884–8.
23.
HuhtinenK., SuvitieP., HiissaJ.Serum HE 4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer2009; 100: 1315–9.
24.
MolinaR., EscuderJ.M., AugeJ.M.HE 4 a novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynecological diseases. Tumor Biol2011; 32: 1087–95.
25.
MooreR.G., MillerM.C., SteinhoffM.M.Serum HE 4 levels are less frequently elevated than CA 125 in women with benign gynecologic disorders. Am J Obstet Gynecol2012; 206 (4): 351.e1–8.
26.
HallamaaM., SuvitieP., HuhtinenK., MatomakiJ., PountanenM., PerheentupaA.Serum HE 4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthly premenopausal women. Gynecol Oncol2012; 125 (3): 667–72.
